Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.
Stéphanie Lheureux, MD, PhD
Advertisement
Stéphanie Lheureux, MD, PhD, is a clinician investigator in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre.
Articles by Stéphanie Lheureux, MD, PhD
Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
The OncFive: Top Oncology Articles for the Week of 7/12
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5